← Back to Clinical Trials
Recruiting NCT06172335

Effects of Cetoleic Acid on Atherosclerosis (Ketolinsyre's Effekt på Aterosklerose)

Trial Parameters

Condition Metabolic Syndrome
Sponsor Oslo University Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 70
Sex ALL
Min Age 20 Years
Max Age 70 Years
Start Date 2024-01-03
Completion 2024-12-30
Interventions
Cetoleic acidControl oil

Brief Summary

In this Randomized Controlled Trial (RCT) we want to study the effect of an oil with high concentrations of cetoelic acid (C22:n1-11) (intervention) compared to supplements with a low concentration of cetoleic acid (control), but with equivalent content of EPA og DHA, on plasma levels of epa and dha as well as atherosclerotic markers, glucose, c-peptide and triglycerides in a patient group with a metabolically unfavorable phenotype. Our primary endpoints are changes in the concentration of EPA and DHA in plasma.

Eligibility Criteria

Inclusion Criteria: * Triglycerides \> 1.7 mmol/L * Waist measurement \> 80 cm (women) and \> 94 cm (men) Exclusion Criteria: * Chronic disease (liver/kidney/metabolism) * Ongoing active cancer treatment * Excessive alcohol consumption (\>40g/day) * Pregnant/breastfeeding or planned pregnancy during the intervention * High intake of fish (\>3 weekly meals) * Level of free thyroxine (T4) and triiodothyronine (T3) outside reference ranges. * Hypertension (≥ 160/ 100 mmHg) * Total cholesterol \> 7.8 mmol/L * Blood donation during the intervention period * Difficulty following the protocol * Smoking or sniffing * Regular use (\> 1 day/week) of anti-inflammatory drugs * Regular use of omega-3 supplements/cod liver oil * Drug use other than stable use of statins, hypertension drugs (Ca antagonists, diuretics and beta blockers). * Hormonal treatment excluding stable use of thyroxine and birth control pills/contraceptive rod

Related Trials